+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sarepta Therapeutics - logo

Sarepta Therapeutics is a biopharmaceutical company that focuses on the development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD). It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Casimersen - Drug Insight and Market Forecast - 2030 - Product Thumbnail Image

Casimersen - Drug Insight and Market Forecast - 2030

  • Report
  • August 2020
  • 80 Pages
  • Global
From
From
From
Vaccine Contract Manufacturing Market Report 2023-2033 - Product Thumbnail Image

Vaccine Contract Manufacturing Market Report 2023-2033

  • Report
  • May 2023
  • 375 Pages
  • Global
From
RNA Based Therapeutics and Vaccines Market Report 2022-2032 - Product Thumbnail Image

RNA Based Therapeutics and Vaccines Market Report 2022-2032

  • Report
  • October 2022
  • 213 Pages
  • Global
From
From
From
Dystrophin - Pipeline Review, H2 2020 - Product Thumbnail Image

Dystrophin - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 128 Pages
  • Global
From
Translational Regenerative Medicine Market Report 2024-2034 - Product Thumbnail Image

Translational Regenerative Medicine Market Report 2024-2034

  • Report
  • February 2024
  • 270 Pages
  • Global
From
Regenerative Medicine Market Report 2023-2033 - Product Thumbnail Image

Regenerative Medicine Market Report 2023-2033

  • Report
  • March 2023
  • 232 Pages
  • Global
From
From
Collaboration Deals in Pharmaceuticals 2019-2024 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2019-2024

  • Report
  • March 2024
  • 1000 Pages
  • Global
From
From
Duchenne Muscular Dystrophy - Global Clinical Trials Review, H2, 2021 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Global Clinical Trials Review, H2, 2021

  • Clinical Trials
  • November 2021
  • 223 Pages
  • Global
From
Loading Indicator